Advisory Panel Questions Huntington’s Scale During Review Of Xenazine
Executive Summary
That Prestwick Pharmaceutical's Xenazine's significant efficacy in treating the involuntary movements (chorea) of Huntington's Disease did not translate to a benefit over placebo for non-motor endpoints may be the fault of an inadequate scale to measure functionality, an FDA panel said
You may also be interested in...
Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial
The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.
Does Xenazine's Effect On Chorea Outweigh Risks? Ask The Patients
Including patient-reported outcomes in the pivotal Xenazine trials could have provided valuable insight into the "net benefit" of the drug as FDA struggled to weigh the difficult combination of positive effects on one major symptom of Huntington’s disease and potential negative effects on other symptoms, FDA review documents suggest.
Does Xenazine's Effect On Chorea Outweigh Risks? Ask The Patients
Including patient-reported outcomes in the pivotal Xenazine trials could have provided valuable insight into the "net benefit" of the drug as FDA struggled to weigh the difficult combination of positive effects on one major symptom of Huntington’s disease and potential negative effects on other symptoms, FDA review documents suggest.